RGNX missed EPS expectations by 33.31%
Mar 05, 2026, 11:39 PM
0.00%
What does RGNX do
REGENXBIO, a clinical-stage biotechnology company based in Rockville, Maryland, specializes in gene therapy using its NAV Technology Platform for retinal, neuromuscular, and neurodegenerative diseases. Its key therapies include ABBV-RGX-314, RGX-202, and RGX-121.
Regenxbio (RGNX) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Regenxbio's actual EPS was -$1.30, missing the estimate of -$0.98 per share, resulting in a -33.31% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.